Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease.
Teriparatide (Parathyroid hormone (PTH) 1-34) has been shown to increase bone mineral density (BMD) and reduce the risk of vertebral fractures when given intermittently. In contrast primary hyperparathyroidism (PHPT) is associated with increased bone loss. Moreover an increased occurrence of cardiovascular disease (CVD) is seen in PHPT patients. The N-terminal fragment of the pro-peptide of Brain Natriuretic peptide (NT-proBNP), a risk marker of CVD, has been shown to be elevated in PHPT patients, indicating that continuously high concentrations of PTH affect the heart. Therefore the aim of this study was to investigate whether teriparatide treatment is associated with changes in plasma NT-proBNP. A total of 42 patients receiving teriparatide treatment were included in the study. Blood samples were taken at baseline, and after 1, 3 and 6 months of treatment. Plasma concentrations of NT-proBNP were measured. Plasma concentrations of ionized calcium, PTH and alkaline phosphatase (ALP) were also analyzed, and BMD for the lumbar spine and total hip was recorded at baseline and after 6 months. Data from 10 men and 32 women, mean age 68 years, were included in the analysis. No effect of teriparatide on plasma concentrations of NT-proBNP was observed at any time points. Ionized calcium and ALP concentrations in the plasma increased after 6 months of treatment, whereas PTH concentrations decreased. Spine BMD T-score was significantly increased after 6 months of treatment. After 6 months of treatment with teriparatide, it did not change the concentration of NT-proBNP in plasma, suggesting that intermittent exposure to therapeutic levels of teriparatide does not affect heart function.